Brawn Biotech — 360° view

Brawn Biotech, a company in the Pharmaceuticals industry, reported revenue of ₹5.62 crore and net profit of ₹0.03 crore for the September 2026 quarter.

Brawn Biotech (BSE: BRAWN) closed at ₹20.25 on 20 Nov 2026, down 3.6% over the past year. Its market capitalisation is ₹6 crore and it trades at 7.5 times earnings.

Share price
₹20.25 (20 Nov 2026)
Market cap
₹6 Cr (20 Nov 2026)
P/E
7.50 (20 Nov 2026)
Revenue
₹6 Cr (September 2026 quarter)
Net profit
₹0 Cr (September 2026 quarter)
ROCE
0.00% (FY26)
ROE
24.4% (FY26)
Book value
₹15.1 (FY26)
Dividend yield
0.00% (FY26)
52-week high / low
₹26.64 / ₹17.71 (20 Nov 2026)
1-year return
-3.6% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
BSE: BRAWN

Incorporated in 1985, Brawn Biotech Ltd is in the business of trading pharmaceutical products

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.